Conference Coverage

Precision CAD testing shows 70% cut in composite risk at 1 year


AT AHA 2022

New protocol called preferred approach

On the basis of these results, Dr. Douglas called the precision strategy “a preferred approach in evaluating patients with stable symptoms and suspected coronary disease.”

Julie Indik, MD, PhD, a professor of medicine at the University of Arizona, Tuscon, said that application of this approach in routine care could have “a major impact on care” by avoiding unnecessary tests with no apparent adverse effect on outcomes.

Although not demonstrated in this study, Dr. Indik suggested that the large number of patients tested for CAD each year – she estimated 4 million visits – means that less testing is likely to have a major impact on the costs of care, and she praised “the practical, efficient” approach of the precision strategy.

Dr. Ron Blankstein, director of Cardiac Computed Tomography, Brigham and Women's Hospital, Boston Ted Bosworth/MDedge News

Dr. Ron Blankstein

Ron Blankstein, MD, director of cardiac computed tomography, Brigham and Women’s Hospital, Boston, also said these data “have both economic and safety implications.” As an AHA-invited discussant of this study, he emphasized that this is a strategy that should only be applied to lower risk patients with no prior history of CAD, but, in this group, he believes these data “will inform future guidelines.”

Dr. Douglas declined to speculate on whether the precision strategy will be incorporated into future guidelines, but she did say that the PRECISE data demonstrate that this approach improves quality of care.

In an interview, Dr. Douglas suggested that this care pathway could provide a basis on which to demonstrate improved outcomes with more efficient use of resources, a common definition of quality care delivery.

Dr. Douglas reported financial relationships with Caption Health, Kowa, and Heartflow, which provided funding for the PRECISE trial. Dr. Indik reported no potential conflicts of interest. Dr. Blankstein reported financial relationships with Amgen, Caristo Diagnostics, and Novartis.


Recommended Reading

Triglyceride-lowering fails to show CV benefit in large fibrate trial
MDedge Cardiology
Diuretic agents equal to prevent CV events in hypertension: DCP
MDedge Cardiology
In CABG, radial artery works best for second key graft: RAPCO at 15 years
MDedge Cardiology
Moving the needle: SGLT2 inhibitor role for isolated kidney disease
MDedge Cardiology
ISCHEMIA-EXTEND: Conservative stable CAD management holds up
MDedge Cardiology